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Desferrioxamine therapy in hemodialysis patients with aluminum-
associated bone disease. Aluminum toxicity in dialysis patients is asso-
ciated with decreased bone turnover and a relative parathyroid hor-
mone (PTH) deficiency. Desferrioxamine (DFO). a chelating agent, has
been reported to improve bone histology in aluminum associated, low
turnover bone disease in dialysis patients not subjected to parathyroid-
ectomy. Information on the effect of DFO therapy on parathyroid gland
function is lacking. In the present study, in addition to changes in bone
histology, parathyroid gland function was evaluated in 18 hemodialysis
patients with aluminum associated, low turnover bone disease (osteo-
malacia and aplastic bone disease) before and after one year of DFO
treatment (Ito 6 glweek). Parathyroid gland function was assessed by
using a calcium free and high calcium (3.5 to 4 mEq/liter) hemodialysis
bath. A comparison of findings before and after DFO treatment re-
vealed the following: I) no difference in serum calcium, phosphorus.
alkaline phosphatase, albumin, and aluminum: 2) a decrease in stainable
trabecular bone aluminum (P < 0.001). and an increase in osteoblastic
osteoid (P <0.03), osteoclasts/mm2 (P <0.01), and bone formation rate
(P < 0.008);3) in previously parathyroidectomized patients, an increase
in osteoblastic osteoid (P < 0.02). osteoclasts/mm2 (P < 0.02). and bone
formation rate (P <0.001); 4) a shift of the PTH-calcium curve to the
right; thus, for similar levels of serum calcium, the PTH concentration
was increased after DFO; 5) an increase in the PTH concentration (P <
0.02) at the serum calcium level required for maximum PTH inhibition:
6) an increase in the serum calcium level (P < 0.02) at the set point for
PTH (the serum calcium concentration required to suppress PTH by
50%); and 7) no difference in maximum PTH stimulation induced by
hypocalcemia. In conclusion, in patients with aluminum associated, low
turnover bone disease: I) aluminum removal from bone may improve
bone histology even in patients with total parathyroidectomy: 2) alumi-
num accumulation may be an important factor in the PTH deficiency:
and 3) DFO therapy appears to result in increased PTH secretion per
individual parathyroid cell.
Aluminum associated osteomalacia and aplastic bone disease
have been recognized as important clinical manifestations of
renal osteodystrophy in maintenance dialysis patients for ap-
proximately a decade. Evidence implicating aluminum as the
causal agent has included: I) the epidemiological association
with high aluminum content of the dialysate [I, 2]; 2) the
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decreased incidence after removal of aluminum from the dialy-
sate [3]; 3) the induction of similar bone disease by aluminum
administration in animal models [4—6]; 4) the association with
stainable bone aluminum [7]; and 5) the beneficial effect of
desferrioxamine (DFO), a chelating agent, in aluminum removal
and the resulting improvement in clinical manifestations and
bone histology in dialysis patients with these disorders [8—10].
In addition to aluminum accumulation in bone, a relative
deficiency of parathyroid hormone (PTH) is a frequent finding
in patients with low turnover, aluminum bone disease [11, 12].
In vitro studies of aluminum and parathyroid glands have
shown that aluminum directly suppresses PTH secretion [13,
14]. Clinical studies have demonstrated that a deficiency of
PTH is present in aluminum associated osteomalacia. O'Hare
and Murnagham. while changing hemodialysis patients from a
dialysate high in aluminum to one in which aluminum was <10
mcglliter, observed that despite no change in serum calcium
concentration, the serum PTH levels increased as the serum
aluminum concentration fell [15]. Furthermore, dialysis pa-
tients with aluminum associated, low turnover bone disease in
which sustained hypocalcemia was induced with a calcium free
dialysis did not increase PTH secretion appropriately [16, 17].
Thus, it would appear that these patients have inappropriately
low PTH levels for uremia, and aluminum may be the direct
cause of the low PTH levels.
Finally, a marked reduction in PTH secretion may predispose
dialysis patients to the development of aluminum associated,
low turnover bone disease. Several reports have documented
the development of both osteomalacia and aplastic bone dis-
ease. or an increased rate of aluminum accumulation after
parathyroidectomy [18—21].
In the present study, patients with aluminum associated, low
turnover bone disease were evaluated with both a calcium free
and a high calcium dialysis before and after one year of therapy
with DFO. This permitted the evaluation of PTH secretion over
a wide range of serum calcium, and thus the development of a
PTH-calcium curve. In addition to the determination of maxi-
mum PTH stimulation and inhibition, the set point of PTH was
also evaluated. The concept of set point, originally developed in
tissue cultures of parathyroid glands [22, 23], is defined as the
concentration of serum calcium which suppresses maximum
PTH secretion by 50 percent. The purpose of this study was to
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determine whether long term therapy with DFO produced an
improvement in clinical manifestations, bone histology, and if
this was associated with changes in PTH secretion, including
maximum stimulation and inhibition, and the set point.
Methods
Eighteen maintenance hemodialysis patients with bone bi-
opsy proven, aluminum associated, low turnover bone disease
were studied. Some of the 18 patients were biopsied because of
findings suggestive of aluminum associated, low turnover bone
disease, their long duration of dialysis, or previous parathyroid-
ectomy. However, the majority were discovered during routine
bone biopsies performed in the dialysis population. There were
4 males and 14 females, with a mean age of 58 3 years, (range
40 to 75 years) on chronic maintenance hemodialysis from I to
14 years (mean 4 I years) at the initiation of the study. Four
patients had a previous total parathyroidectomy and one a
subtotal parathyroidectomy. In two patients, diabetic nephrop-
athy was the cause of renal failure. At the beginning of the
study, four patients were receiving 0.25 mcg/day of 1,25
(OH)2D. This was continued throughout the course of the
study. No other patients received vitamin D metabolites or
analogs.
Patients were eligible for inclusion into the study provided
that the bone formation rate was <106 tm2/mm2/day, endosteal
fibrosis was <0.5% of the total trabecular surface, and stainable
trabecular bone aluminum was greater than 20% of the total
trabecular surface. If all the above criteria were fulfilled and
relative osteoid volume was greater than 12%, the bone was
termed osteomalacia; if the relative osteoid volume was less
than 12%, the bone was termed aplastic. By these criteria, at
the start of DFO therapy, four patients had osteomalacia and 14
had aplastic bone disease.
After bone biopsy confirmed the diagnosis of low turnover,
aluminum bone disease, a calcium free and a high calcium (3.5
to 4 mEq/liter) hemodialysis was performed on separate days.
During the calcium free hemodialysis, the serum calcium was
measured every 15 minutes with an automated calcium analyzer
(Calcette. Precision Systems Inc. Sudsbury, Massachusetts,
USA). When the serum calcium decreased to less than 7.0 mgI
dl, the dialysate calcium concentration was changed to 3.5
mEq/liter. Similarly, during the high calcium dialysis, serum
calcium and PTH were measured every 15 to 30 minutes
throughout the dialysis. After completion of the high and
calcium free dialysis, treatment with DFO was begun. Desfer-
rioxamine, Ito 6 grams per week, was given for one year during
the last one to two hours of hemodialysis. During therapy with
DFO, aluminum containing antacid therapy was not changed,
and was administered to maintain the serum phosphorus at
levels less than 5 mgldl.
After one year of treatment with DFO, the calcium free and
high calcium dialysis were repeated. In addition, a repeat
double tetracycline-labeled, anterior iliac crest bone biopsy was
obtained.
Parathyroid hormone was measured with the Allegro assay
(Nichols, San Juan Capistrano, California, USA), which mea-
sures only intact PTH. Previous studies with this assay in
chronic renal failure patients have shown the mean PTH value
in osteitis fibrosa to be 923 pg/mI (range 460 to 1983 pg/mI) and
in osteomalacia and aplastic bone disease 103 pg/mI (range 5 to
Serum calcium ing/dI
Serum phosphorus ing/di
Serum alkaline
phosphatase lU/liter
Serum albumin g/dl
Serum aluminum pg/liter
Serum PTH pg/nil
Mean SE
9.6 0.2 9.5 0.2 8.5—10.5
5.2 0.3 5.6 0.5 2.5—4.5
110 8 121 16 40—115
3.9 0.1 3.9 0.1 3.5—5.0
162±29 186±28 <5
101 30 113 30 10—65
240 pg/mI) [24]. Serum samples from pre-DFO studies were
frozen at —70°C and matched with serum samples from post
DFO studies in the same patient. The validity of storing frozen
serum has been shown previously [24]. Intra-assay variation
was less than 5%.
The following terms were used to define the serum calcium-
PTH curve; calciummin—the level of serum calcium at which
PTH was maximally stimulated and below which no further
stimulation of PTH was observed; calciummax—the lowest
serum calcium concentration that maximally suppressed PTH
and above which no further suppression of PTH was observed;
the set point of PTH secretion was defined as the serum calcium
concentration at which PTH was 50% suppressed. This value
was obtained by assigning the maximum PTH level as 100%.
Serum albumin, calcium, phosphorus, and alkaline phospha-
tase were measured by standard laboratory techniques. Serum
aluminum was measured by flameless atomic absorption with a
graphite furnace [25].
The iliac bone biopsies were processed as previously de-
scribed [12]. Measurements of trabecular bone were made in
the following categories: I) osteoblastic osteoid, the fraction of
trabecular surface covered by osteoblasts; 2) osteoclasts/mm2,
the number of osteoclasts per square millimeter of cancellous
bone; 3) relative osteoid volume, the fraction of trabecular bone
volume occupied by osteoid; 4) bone volume, the fraction of
cancellous bone volume occupied by bone matrix; 5) bone
appositional rate, the mean distance between tetracycline labels
divided by the number of days between doses of tetracycline; 6)
bone formation rate, which was obtained by multiplying the
bone appositional rate by the length of the bone surface
occupied by double tetracycline labels; and 7) stainable trabec-
ular bone aluminum, the fraction of trabecular bone surface
covered with aluminum.
Biochemical and histomorphometric measurements were an-
alyzed using paired i-test to compare results from the same
patients and unpaired t-test for comparison of different popula-
tions. Regression analysis was used to calculate the slope of
PTH-calcium relationship. All results represent the mean SE.
Results
Before therapy with DFO, 17% of the patients were confined
to a wheelchair, 6% used a cane or crutches, 67% had diffuse
musculoskeletal pain, and 22% had skeletal fractures, After
therapy with DFO, 22% were confined to a wheelchair, 6% used
a cane or crutches, 33% had diffuse musculoskeletal pain, and
the incidence of skeletal fractures had decreased to 0%.
Biochemical data before and after DFO therapy are shown in
Table 1. In the 18 patients, including the five patients with a
Table I. Biochemical data pre- and post-DFO treatment
Normal
Pre Post range
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Table 2. A pre- and post-DF0 comparison of parathyroid hormone and bone histology between parathyroi
patients with aluminum associated, low turnover bone disease
dectomized and parathyroid intact
Bone
Relative Formation
Aluminum Osteoblastic Osteoid Rate Basal PTH Maximum PTH
Stain (%) Osteoid (%) Osteoclasts/mm2 Volume (%) (m2/mni/day) (pg/mi) (pg/mi)
Pre Post Pre Post Pre Post Pre Post Pre Post Pre Post Pre Post
0"
P < 0.03
Pre Post
Bone formation
rate
Pre Post Pre Post
Fig. 1. The comparison of bone histology parameters before and after
DFO therapy are shown. Those include stainable trabecular bone alumi-
num, osteoblastic osteoid, osteoclasts/mm2, bone formation rate, relative
osteoid volume, and bone volume. Values represent the mean SE.
previous parathyroidectomy, there were no significant changes
in serum calcium, phosphorus, alkaline phosphatase, albumin,
aluminum, or PTH.
Results of bone histology before and after DFO therapy are
presented in Figure 1. Stainable trabecular bone aluminum
decreased from 44 4.1 to 13 3.4% (P <0.001) of the total
trabecular surface. Osteoblastic osteoid increased from 1.5
0.5 to 6.2 2.0% (p < 0.03) of the total trabecular surface.
Osteoclasts/mm2 increased from 0.3 0.07 to 1.0 0.23 (P <
0.01). The bone formation rate at the tissue level increased from
13 7 to 669 187 m2/mm2/day (P < 0.008). Neither the
relative osteoid volume nor bone volume significantly changed.
Five patients had a parathyroidectomy (4 total and I subtotal)
prior to entry into the present study. The baseline PTH level in
the four patients with previous total parathyroidectomy was
less than 10 pg/mi, and in the one patient with previous subtotal
parathyroidectomy, 54 pg/mi. Thus, the four patients with a
previous total parathyroidectomy, and both low baseline and
maximally stimulated PTH levels, were included as a group and
compared to the other 13 patients with intact parathyroid
glands. In both the PTX and parathyroid intact groups, the
basal PTH after DFO is corrected for the serum calcium level.
These results are shown in Table 2. Although baseline and
maximally stimulated PTH levels remained very low before and
after DFO in the parathyroidectomized group, stainable bone
aluminum decreased and osteoblastic osteoid, osteoclasts/mrn2,
and bone formation rate increased. However, before DFO,
compared to the other patients, parathyroidectomized patients
had decreased osteoblastic osteoid (P < 0.02), osteoclasts/mm2
(P < 0,02), and bone formation rate (P < 0.001). After DFO
treatment, only osteoblastic osteoid approached a significant
difference (P < 0.06). All other categories of bone histology
were comparable in the two groups. Both basal and maximally
stimulated PTH were less before and after DFO in the parathy-
roidectomized group.
Parathyroid hormone stimulation and suppression were eval-
uated with a calcium free and high calcium dialysis both before
and after DFO therapy. Excluding the patients with previous
parathyroidectomy. the entire spectrum of the PTH response to
varying serum calcium concentration before and after DFO
Parathyroid-
ectomized
patients
Parathyroid
intact
patients
Normal
values
Mean SE
45 25 0.l5 2,3b 0.06" 057b 12.1 7.7
±11 ±8 ±0.2 ±0.4 ±0.004 ±0.22 ±7.9 ±1.8
0 0.76 ± 0.24"
45 b 1.85 74h 0.32 116h 7.4 6.9 19 711b 137 171b 432 444
±4 ±3 ±0.6 ±2.4 ±0.09 ±0.26 ±1.4 ±1.7 ±9.9 ±235 ±42 ±44 ±110 ±105
o47 3.i 8.8
±216 ±0.8 ±5.5
0.21 ± 0.07" 2.54 ± 0.39" 1002d
7,3a 14.4"
±1.7 ±7.0
P < 0.05 as compared with parathyroid intact patients ("); as compared with pre-DFO (b)
" Value from Reference 36d Value from Reference 9
10—65
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Osteoid
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therapy is shown in Figure 2. After one year of DFO therapy,
the PTH-calcium curve was shifted to the right. Thus, for
similar levels of serum calcium, the concentration of PTH was
increased after DFO therapy. In addition, at the steepest part of
the PTH-calcium curve, the slope of both curves was not
significantly different, —0.452 0.044 vs. —0,444 0.038,
before and after DFO treatment. Thus, the rate of increase in
PTH secretion was similar before and after DFO treatment. The
concentration of PTH at maximum inhibition was greater after
DFO therapy, 68 27 versus 92 34 pg/mI (P < 0.02; Fig. 3).
The serum calcium levels at which maximum inhibition of PTH
was observed (calciummax) were 10.64 0.17 and 10.57 0.12
mg/dl (NS), respectively. The levels of maximally stimulated
PTH (432 105 vs. 444 99 pg/mI), were not different before
and after DFO therapy (Fig. 4). However, the serum calcium
level at which maximum stimulation was observed (calciummin)
was significantly greater after DFO therapy, 7.72 0.11 vs.
7.96 0.18 mgldl (P < 0.02). As shown in Figure 5, the serum
calcium level at the set point of PTH (50% reduction) was
greater after DFO (8.8 0.16 vs. 9.26 0.18 mg/dl, P < 0.02).
Thus, after DFO, a higher serum calcium concentration was
necessary to suppress PTH at the set point for PTH.
The serum PTH concentration at baseline serum calcium was
compared before and at the end of DFO therapy in the 13
patients with intact parathyroid glands. Since the pre- and
post-DFO baseline serum calcium levels were not the same in
all the patients, the post-DFO baseline PTH concentration was
corrected to the serum calcium level obtained pre-DFO. The
corrections were determined from the PTH-calcium curve
available after DFO for each patient. The results are displayed
in Figure 6. At a serum calcium of 9.42 0.17 mg/dl. the PTH
levels increased in 11 patients and remained the same in two
patients. Overall, serum PTH increased from 137 42 to 171
44 pg/mI (P < 0.003).
Fig. 2. P/oiled on the graph is the percent
decrease in PTH as i/ic serum calcium
concentration increases. The 100% value for
PTH represents the maximum PTH
concentration obtained during sustained
hypocalcemia as a result of a calcium free
dialysis. The remainder of the data points
were obtained during calcium free and high
calcium dialysis. The pre-DFO values are
represented with closed circles and post-DFO
values with open circles. P values are written
12 above the open circles. Parathyroidectomizedpatients were excluded. Values represent the
mean SE.
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Fig. 3. The individual PTH levels at ,naximal inhibition pre- and post-
DFO therapy are displayed. This value represents the PTH concentra-
tion at which a further increase in serum calcium concentration pro-
duced no additional inhibition of PTH. Parathyroidectomized patients
were excluded.
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Pre- Post-
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Fig. 4. The individual PT!-! levels at ,naxjmu,n stimulation pre— and
post -DFO therapy are shown. This value represents the level of PTH at
which a further decrease in serum calcium did not produce an additional
increment in PTH. There was no difference in mean PTH values before
and after DFO therapy. Parathyroidectomized patients were excluded.
Discussion
In the present study, the effect of DFO therapy in 18
maintenance hemodialysis patients with aluminum associated.
low turnover bone disease was evaluated with regard to clinical
status, bone histology, and parathyroid gland function. While
severe aluminum-associated bone disease can be encountered
in dialysis patients with either mixed uremic osteodystrophy or
osteitis fibrosa, this study evaluated patients only with alumi-
num associated, low turnover bone disease. Therapy with DFO
resulted in moderate clinical improvement, decreased stainable
trabecular bone aluminum, improved bone histology, and in-
creased PTH secretion. Changes in PTH included increased
baseline PTH levels (corrected for serum calcium). PTH levels
at maximum inhibition, and PTH levels at the set point.
However, maximum PTH levels induced by hypocalcemia did
not change.
During treatment none of the patients reported worsening of
the musculoskeletal symptoms or developed fractures. How-
ever, at the same time, improvement in symptoms was perhaps
not as dramatic as reported previously by others: these studies
included mostly symptomatic and debilitated patients 19. 10].
Our study patients were obtained from a representative dialysis
Fig. 5. The individual seru,n calcium concentrations at the set point
for PTH pre- and post-DFO therapy are displayed. The set point for
PTH was defined as the serum calcium concentration at which PTH was
50% suppressed. This value was obtained by assigning the maximum
PTH level as 100%. Parathyroidectomized patients were excluded.
population and did not include only patients with marked
clinical deterioration and multiple fractures. Consequently, it
may be more difficult to appreciate clinical changes or the
advanced form of the disease as reported by others may
respond differently. In addition, a control untreated population
was not available for comparison. However, many of these
patients, untreated, have developed symptomatic bone disease
[12].
From the present study it is difficult to ascertain the optimal
dose of DFO in the treatment of aluminum associated, low
turnover bone disease. The dose of intravenous DFO employed
ranged from I to 6 grams per week. At the conclusion of the
study we could not detect any differences in either bone
histology or PTH responses when the different doses of DFO
were compared. With a similar range of weekly DFO, Charhon
et al could not detect differences in the bone histology [10].
Recent data have indicated that one gram of intravenous DFO
removed 77% as much aluminum as a 2 gram intravenous dose
1261. Since recent reports have documented fatal rhizopus
infections in hemodialysis patients receiving DFO [27, 28], it
may be advisable to use the lowest effective dose of DFO.
In the 18 patients studied, including the five parathyroidec-
tomized patients, no change in serum calcium, phosphorus,
alkaline phosphatase. albumin, aluminum, and PTH was ob-
served after one year of DFO treatment. This is in agreement
P < 0.02
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Fig. 6. The comparison of the individual PTH concenlrations and
post-DFO therapy. The post-DFO PTH concentration was corrected to
the serum calcium level obtained before DFO. The correction was made
on the basis of the PTH-calcium curve obtained for each patient.
Parathyroidectomized patients were excluded.
with the observations of Charhon et al [10]. The baseline serum
aluminum concentration was also similar to that reported by
others [9, 10]. In the present study, aluminum containing
antacids were continued and the post-DFO serum aluminum
level did not change. The two other studies of dialysis patients
with low turnover, aluminum bone disease did not report serum
aluminum levels at the end of DFO therapy [9, 10]. In another
study with mixed histologic types, seven patients with in-
creased stainable trabecular bone aluminum, only two with
aluminum associated, low turnover bone disease, were treated
with DFO, and baseline serum aluminum levels were not lower
after six to ten months of DFO [8]. In the present study,
dialysate aluminum was checked frequently and found to be
consistently below 10 mcglliter. Thus, the failure to observe
changes in serum aluminum levels was most likely secondary to
continued ingestion of aluminum-containing antacids. In addi-
tion, the continued DFO administration, by recruiting alumi-
num from tissue, may also have played a role. Baseline serum
PTH levels did not change after DFO, but these measurements
included the parathyroidectomized patients.
There was a significant improvement in bone histology after
one year of therapy with DFO. In addition to a marked decrease
in stainable trabecular bone aluminum, an increase in osteoblas-
tic osteoid, osteoclasts/mm2, and the bone formation rate was
observed. These findings are consistent with previous studies
[8—10]. As opposed to the findings by Charhon et al [10], our
group of patients with aplastic bone disease significantly de-
creased stainable trabecular bone aluminum and increased
osteoblastic osteoid, osteoclasts/mm2, and the bone formation
rate. Since the response to DFO was not different in patients
with osteomalacia or aplastic bone disease, in this study, as in
the study by Andress et al [9], patients with osteomalacia or
aplastic bone disease were analyzed as a single group.
In our study patients, the findings suggest that before alumi-
num removal the level of PTH may have a greater influence on
bone cell activity than after aluminum removal. Before DFO,
the parathyroidectomized group, with lower PTH levels, had
decreased osteoblastic osteoid and osteoclasts/mm2 as com-
pared with the parathyroid intact group. Thus, it is possible that
the lower PTH levels contributed to these findings. However,
after DFO, despite continued differences in PTH levels, bone
histologic parameters were not different between the two
groups: only osteoblastic osteoid approached significance (P <
0.06).
Of considerable interest was the finding that in the parathy-
roidectomized group, DFO therapy resulted in an increase in
osteoblastic osteoid, osteoclasts/mm2, and bone formation rate
despite only minimal changes in PTH. At the same time,
stainable trabecular bone aluminum decreased. Thus, these
findings differ from the parathyroidectomized patients studied
by Andress et al [9], in whom no change in bone histology was
observed after DFO therapy.
A possible explanation for the failure to observe improve-
ment in the aplastic bone disease group of Charhon et alt 10]
and the parathyroidectomized group of Andress et al [9] is that
in both groups, stainable trabecular bone aluminum remained
high even after DFO therapy. Thus, in the aplastic bone disease
group, stainable trabecular bone aluminum only decreased from
65 13 to 42 17% and in the parathyroidectomized group
from 64 7 to 46 9%. In the present study, the stainable
trabecular bone aluminum decreased with DFO therapy from 44
4% to less than 20% in all patients except one. Thus, it is
possible that with DFO therapy, patients with aplastic bone
disease or previous parathyroidectomy decrease stainable tra-
becular bone aluminum at a slower rate. However, once stain-
able bone aluminum is lowered below a critical threshold,
improvement in bone histology may occur. In support of this
hypothesis is the study by Salusky et al in which dialysis
patients with greater than 30% stainable bone aluminum had
only a normal or reduced bone formation rate [291.
As a result of the calcium free and high calcium dialysis, PTH
stimulation and suppression were evaluated through a wide
range of serum calcium. The patients with a previous parathy-
roidectomy were excluded from analysis. In the remaining
patients, the PTH-calcium curve was shifted to the right after
DFO therapy. Thus, for a given serum calcium, the PTH value
was greater after DFO. We and others have previously shown
that in aluminum associated, low turnover bone disease, hypo-
calcemia-induced P1'H stimulation is decreased [16, 17]. In
addition, in vitro studies have demonstrated that aluminum
decreases PTH secretion by parathyroid cells [13, 14]. Since
serum aluminum levels did not change before and after DFO, it
is unlikely that the observed change in the PTH curve was
influenced by the serum aluminum concentration. A more likely
alternative may be a decrease in parathyroid gland aluminum:
the observed decrease in stainable trabecular bone aluminum
P< 0.003
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after DFO suggests such an alternative which could account for
the observed changes in PTH levels.
The serum calcium level at which PTH is maximally sup-
pressed was not different before and after DFO. However, the
PTH concentration during maximum suppression was higher
after DFO. Neither before nor after DFO therapy was PTH
completely suppressed by hypercalcemia. Previous studies in
non-uremic animals have indicated that PTH is not completely
suppressed even at very high serum calcium levels [30, 31]. Our
findings in these patients would support these observations.
Maximal PTH stimulation induced by hypocalcemia was not
different before and after DFO. This observation, which has
been reported previously [91, suggests that the hyperparathy-
roidism did not increase during DFO therapy. And since
maximal PTH stimulation correlates well with the size of the
parathyroid gland [32, 33], it is likely that an increase in the size
of the parathyroid gland did not occur during the one year of
DFO therapy. In addition, the slope of the steep part of the
PTH-calcium curve was not different (Fig. 2). As suggested by
Parfitt and Kleerekoper [341, if the number of parathyroid cells
remained constant and each cell required a higher level of
calcium to reduce PTH secretion, the slope should remain the
same, while an increased number of parathyroid cells would
increase the slope. Thus, the finding of similar slopes provides
additional evidence that the parathyroid gland mass did not
change. Although maximal PTH stimulation did not increase at
the end of DFO therapy, the serum calcium concentration at
which maximal PTH stimulation was observed increased. This
would suggest that removal of aluminum with DFO somehow
increased the serum calcium concentration at which PTH was
maximally secreted. Further studies on the interrelationship of
aluminum and DFO on PTH secretion need to be performed.
The PTH-calcium curve shifted to the right after one year of
therapy with DFO; since data on the PTH-calcium relationship
for untreated patients with aluminum associated, low turnover
bone disease are not available, it cannot be concluded with
certainty that aluminum removal with DFO produced the im-
proved PTH-calcium curve. However, because of the high
morbidity and mortality associated with aluminum associated,
low turnover bone disease, such data may be impossible to
obtain inasmuch as failure to treat this condition may have
serious consequences [121. However, with a continued alumi-
num burden, it is difficult to conceive that an improved PTH
response would be observed without DFO since the present
data suggest not an increased number of parathyroid cells after
DFO therapy but increased secretion for each individual para-
thyroid cell.
Although the PTH levels were low in our patients, the shape
of the PTH-calcium curve during maximum stimulation and
suppression resembled that observed in normals and patients
with osteitis fibrosa [30, 33]. Consequently, aluminum toxicity
did not appear to destroy the integrity of the parathyroid cell,
but rather preserved normal PTH responsiveness while result-
ing in a downward displacement of the PTH-calcium curve.
Similar results have been observed with in vitro studies of
aluminum toxicity during varying calcium concentration in
parathyroid cell cultures [14].
The concept of the set point of calcium for PTH secretion has
been developed primarily in tissue cultures of parathyroid cells
[22, 23]. Similar data in dialysis patients are not available. In
this study, the set point of calcium for PTH secretion increased
significantly after one year of DFO therapy. This is an impor-
tant finding since this increment occurred at the point of the
steepest change in PTH, and thus is the most sensitive indicator
of parathyroid gland function.
After DFO therapy, the serum PTH concentration corrected
for serum calcium concentration increased in our patients. The
increased PTH concentration may have resulted in an improve-
ment in bone histology. However, an improvement in bone
histology was also observed in the parathyroidectomized pa-
tients after DFO therapy despite virtually no change in PTH
levels. Since previous studies in dialysis patients have shown a
correlation between the levels of PTH and osteoblastic osteoid,
bone resorption, and bone formation rate [35, 361, the increased
PTH concentration may have contributed to the improvement
in bone histology observed in parathyroid intact patients. This
possibility requires further evaluation since recent studies
which have reported an improvement in bone histology after
DFO therapy, differed in their PTH results. While Charhon et al
[10] observed an increase in PTH levels, Andress et al [9] did
not.
In summary, 18 patients with aluminum associated, low
turnover bone disease were treated with DFO for one year.
After one year of DFO, stainable trabecular bone aluminum
decreased and bone histology improved even in patients with
prior parathyroidectomy. The PTH-calcium curve evaluated
over a wide range of serum calcium was shifted to the right after
DFO. Thus, for the same calcium concentration, the PTH level
was increased after DFO. However, the maximum PTH con-
centration induced by hypocalcemia was not different before
and after DFO. In conclusion, these findings indicate that
aluminum removal results in increased bone activity and may
improve parathyroid gland function.
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